Forbes Medi-Tech Sells Andro Business
VANCOUVER, British ColumbiaForbes Medi-Tech Inc. (NASDAQ:FMTI) sold its pharmaceutical fine chemicals business, which focused on process technologies for androstenedione and androstadienedione, to an unnamed multi-national pharmaceutical company. The sale gave the company $1.9 million in gross proceeds. This initiative is in line with Forbes streamlined focus on generating revenue for its nutraceutical business.
For more information, visit www.forbesmedi.com or Booth #4807 at the IFT Food Expo.